1	A preliminary study on serological assay for severe acute
2	respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238
3	admitted hospital patients
4	
5	Lei Liu ^{1*} , Wanbing Liu ^{1*} , Yaqiong Zheng ¹ , Xiaojing Jiang ² , Guomei Kou ¹ , Jinya
6	Ding ³ , Qiongshu Wang ⁴ , Qianchuan Huang ³ , Yinjuan Ding ¹ , Wenxu Ni ¹ , Wanlei Wu ¹ ,
7	Shi Tang ¹ , Li Tan ⁴ , Zhenhong Hu ² , Weitian Xu ² , Yong Zhang ² , Bo Zhang ² , Zhongzhi
8	Tang ² , Xinhua Zhang ² , Honghua Li ² , Zhiguo Rao ² , Hui Jiang ² , Xingfeng Ren ² ,
9	Shengdian Wang ^{5#} , Shangen Zheng ^{1#}
10	
11	¹ Department of Transfusion, General Hospital of Central Theater Command of PLA,
12	Wuhan 430070, Hubei, China
13	² Department of Infectious Diseases, General Hospital of Central Theater Command
14	of PLA, Wuhan 430070, Hubei, China
15	³ Department of Clinical Laboratory, General Hospital of Central Theater Command
16	of PLA, Wuhan 430070, Hubei, China
17	⁴ Department of Disease Control and Prevention, General Hospital of Central Theater
18	Command of PLA, Wuhan 430070, Hubei, China
19	⁵ CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese
20	Academy of Sciences, Beijing 100101, China
21	
22	[*] These authors contributed equally to this work.
23	
24	[#] Correspondence authors: Prof Shangen Zheng MD, Department of Transfusion,
25	General Hospital of Central Theater Command of PLA, Wuhan 430070, Hubei, China;
26	sxkzsg@sina.com or Prof Shengdian Wang PhD, CAS Key Laboratory of Infection
27	and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,
28	China; sdwang@ibp.ac.cn
•	

30 Abstract

31	Background The outbreak of the recently emerged novel corona virus disease 2019
32	(COVID-19) poses a challenge for public health laboratories. We aimed to evaluate
33	the diagnostic value of serological assay for SARS-CoV-2.
34	Methods A newly-developed ELISA assay for IgM and IgG antibodies against N
35	protein of SARS-CoV-2 were used to screen the serums of 238 admitted hospital
36	patients with confirmed or suspected SARS-CoV-2 infection from February 6 to
37	February 14, 2020. SARS-CoV-2 RNA was detected by real time RT-PCR on
38	pharyngeal swab specimens.
39	Findings Of the 238 patients, 194 (81.5%) were detected to be antibody (IgM and/or
40	IgG) positive, which was significantly higher than the positive rate of viral RNA
41	(64.3%). There was no difference in the positive rate of antibody between the
42	confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85) whose
43	nucleic acid tests were negative. After the patients were defined to the different stages
44	of disease based on the day when the test samples were collected, the analysis results
45	showed that the antibody positive rates were very low in the first five days after initial
46	onset of symptoms, and then rapidly increased as the disease progressed. After 10
47	days, the antibody positive rates jumped to above 80% from less than 50%. On the
48	contrary, the positive rates of viral RNA kept above 60% in the first 11 days after
49	initial onset of symptoms, and then rapidly decreased. In addition, half of the
50	suspected patients with symptoms for 6-10 days were detected to be antibody positive.
51	Interpretation The suspected patients were most likely infected by SARS-CoV-2.

- 52 Before the 11th day after initial onset of symptoms, nucleic acid test is important for
- 53 confirmation of viral infection. The combination of serological assay can greatly
- 54 improve the diagnostic efficacy. After that, the diagnosis for viral infection should be
- 55 majorly dependent on serological assay.
- 56 Keywords. SARS-CoV-2; diagnosis; serological assay; nucleic acid test

58 Introduction

59	A novel betacoronavirus ¹ named severe acute respiratory syndrome coronavirus
60	2 (SARS-CoV-2) causes a recent cluster cases of respiratory illness named corona
61	virus disease 2019 (COVID-19) in multiple regions of the world, and it leads to a
62	serious public health problem especially in Wuhan city, Hubei province, China since
63	December 2019. ² By March 1, 2020, more than 80,000 confirmed cases have been
64	identified globally both in China and other 58 countries spanning Asia, Europe,
65	Oceania, North and South America, and Northeast Africa. It is evidenced that
66	SARS-CoV-2 can transmit rapidly from person to person, which is evidently found in
67	hospital and family settings. ³⁻⁵
68	The SARS-CoV-2 is the seventh member of enveloped RNA coronaviruses
69	(CoVs). ⁶⁻⁸ Sequence and phylogenetic tree of CoVs analysis indicates that
70	SARS-CoV-2 is genetically distinct from SARS-CoV and is more closely related to
71	bat-SL-CoV ZC45 and bat-SL-CoV ZXC21. ¹ SARS-CoV-2 owns a similar
72	receptor-binding domain structure to that of SARS-CoV. ¹ A typical CoV contains four
73	main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N)
74	proteins. The S protein homotrimers are required for attachment to host receptors, ⁹
75	and both the M protein and the E protein play important roles in virus assembly. 10,11
76	The N protein is responsible for packaging the encapsidated genome into virions, ^{12,13}
77	and acts as a viral RNA silencing suppressor that is beneficial for the viral replication.
78	¹⁴ Furthermore, the N protein has high immunogenic activity and is profusely
79	overexpressed during infection, ¹⁵ indicating that N protein should be a potential

80	source of a diagnostic antigen for detecting SARS-CoV-2 infection. Many diagnostic
81	methods based on the N protein have been developed for SARS-CoV detection. $^{16-18}$
82	In addition, different CoVs possess special structural and accessory proteins, such as
83	HE protein, 3a/b protein, and 4a/b protein. ¹⁹
84	Both nucleic acid test and serological assay are commonly used for infectious
85	disease screening and diagnosis. In the present case of SARS-CoV-2, nucleic acid test
86	has been being routinely used to detect causative viruses from respiratory secretions
87	by real-time RT-PCR in China. However, the nucleic acid tests appeared to have a
88	high false negative rate because of several unavoidable reasons, including the
89	sensitivity of the detection kits that have not been well assessed, sampling location
90	and technique, etc. A large number of clinically-suspected patients, whose nucleic
91	acid tests were negative, are unable to get timely confirmed-diagnosis and hospital
92	treatment, which potentially promotes the spread of SARS-CoV-2 and leads to a rapid
93	disease progress of the suspected patients.
94	In this study, a newly-developed IgM and IgG antibody detecting Enzyme-linked
95	immunosorbent assays (ELISA) based on a recombinant fragment of SARS-CoV-2 N
96	protein were used to detect IgM and IgG against SARS-CoV-2 in serum of 238
97	admitted hospital patients with confirmed or suspected SARS-CoV-2 infection. The
98	results strongly indicated that the suspected patients were infected. We also analyze
99	the diagnostic value of the IgM and IgG testing in COVID-19, even in the early stage
100	of disease.

102 Methods

103 Patients and samples

104	All consecutive patients (n=238) with confirmed or suspected SARS-CoV-2
105	infection who have been tested by real-time RT-PCR for viral infection and were
106	being treated in General Hospital of Central Theater Command of PLA from February
107	6 to February 14, 2020, were enrolled. The general information (age, sex, vital signs,
108	coexisting disorders), clinical, laboratory, and radiological characteristics data of the
109	patients on admission were extracted from electronic medical records. Among the 238
110	recruited patients, 153 patients were laboratory-confirmed cases, who were tested
111	positive for viral RNA by real time RT-PCR assay on pharyngeal swab specimens, and
112	the remaining 85 patients having negative results for real time RT-PCR assay were
113	clinically diagnosed as highly-suspected cases according to the notice on the issuance
114	of strategic guidelines for diagnosis and treatment of COVID-19. ²⁰ The serum
115	samples were collected once from each recruited patient. Meanwhile, the serum
116	samples from 70 ordinary patients and 50 healthy blood donors were randomly
117	selected as the controls. The study was approved by the Hospital Ethics Committee
118	and written informed consent was waived for emerging infectious diseases.
119	Real time Reverse Transcription Polymerase Chain Reaction (RT-PCR) Assay
120	Pharyngeal swab specimens were collected from patients and placed into a
121	collection tube with 200 μL of virus preservation solution. Total RNA was extracted
122	using the respiratory sample RNA isolation kit (Shuoshi, Shanghai, China). After
123	vortex, 50 μ L of cell lysates were transferred into another collection tube. The

124	collection tube was	centrifugated at	1000 rr	m/min f	for 5 mir	n after standing at room	n

- temperature for 10 minutes. 5 μL RNA was prepared and used for real time RT-PCR.
- 126 Real time RT-PCR was performed using the nucleic acid testing kit (Daan,
- 127 Guangzhou, China) for SARS-CoV-2 detection. The open reading frame 1ab
- (*ORF1ab*) and nucleocapsid protein (N) were simultaneously selected as the two
- target genes. The human GAPDH gene was used as an internal control. The specific
- 130 primers and probes set for *ORF1ab* and N were as follows: *ORF1ab*-forward primer
- 131 5'-ACCTTCTCTTGCCACTGTAGC-3'; *ORF1ab*-reverse primer
- 132 5'-AGTATCAACCATATCCAACCATGTC-3'; and the probe
- 133 5'-FAM-ACGCATCACCCAACTAGCAGGCATAT-BHQ1-3'; N-forward primer
- 134 5'-TTCAAGAAATTCAACTCCAG-3'; N-reverse primer
- 135 5'-AGCAGCAAAGCAAGAGCAGCATC-3'; and the probe
- 136 5'-VIC-TCCTGCTAGAATGGCTGGCAATGGCG-BHQ1-3'. The real time RT-PCR
- 137 experiment was thoroughly performed according to kit's instructions. The reaction
- mixture contains 17 μ L of reaction buffer A, 3 μ L of reaction buffer B, and 5 μ L RNA
- template. The real time RT-PCR assay was performed under the following conditions:
- 140 incubation at 50 °C for 15 min and 95 °C for 15 min, 45 cycles of denaturation at
- 141 94 °C for 15 s, and extending and collecting fluorescence signal at 55 °C for 45 s. A
- 142 cycle threshold value (Ct-value) ≤ 40 was defined as a positive test result, and a
- 143 Ct-value > 40 was defined as a negative test.

144 Enzyme-Linked Immunosorbent Assay (ELISA)

145 Serological assay was performed using Enzyme-Linked Immunosorbent Assays

146	kit (Lizhu, Zhuhai, China), which was established for detecting IgM or IgG antibody
147	against N protein of SARS-CoV-2. For IgM detection, ELISA plates were previously
148	coated with mouse anti-human IgM (μ chain) monoclonal antibody. 100 μ L diluted
149	(1:100) serum sample was added into the pre-coated plates with three replicating
150	wells for each sample and incubated at 37 °C for 1 h. The heat-inactivated positive
151	and negative serum were included on each plate. After washing, 100 μ L horse radish
152	peroxidase (HRP) conjugated recombinant (rN) protein of SARS-CoV-2 was added.
153	Then the plate was incubated at 37 $^{\circ}\text{C}$ for 30 min followed by washing. 50 μL of
154	TMB substrate solution and 50 μL of the corresponding buffer were added and
155	incubated at 37 °C for 15 min. The reaction was terminated by adding 50 μL of 2 M
156	sulfuric acid, and the absorbance value at 450 nm (A_{450}) was determined. The cut off
157	value was calculated by sum of 0.100 and average A_{450} of negative control replicates.
158	$A_{\rm 450}$ less than cut off value was defined as a negative test, and $A_{\rm 450}$ greater than or
159	equal to cut off value was defined as a positive test.
160	For IgG detection , ELISA plates were previously coated with rN protein. 5 μL
161	serum sample diluted with 100 μ L dilution buffer were added into the plates. After
162	incubation and washing, HRP-conjugated mouse anti-human IgG monoclonal
163	antibody was added into the plates for detection. The other operation steps were
164	performed as described in the above IgM detection. The cut off value was calculated
165	by the sum of 0.130 and average A_{450} of negative control replicates. A_{450} less than cut
166	off value was defined as a negative test, and A_{450} greater than or equal to cut off value
167	was defined as a positive test.

168 Statistical analysis

169	Continuous variables were described as the means and standard deviations or
170	medians and interquartile ranges (IQR) values. Categorical variables were expressed
171	as the counts and percentages. Independent group t tests were applied to continuous
172	variables that were normally distributed; otherwise, the Mann-Whitney test was used.
173	Categorical variables were compared using the chi-square tests, while the Fisher exact
174	test was used when the data were limited. Statistical analyses were performed using
175	Statistical Package for the Social Sciences (SPSS) version 22.0 software. A two-sided
176	α of less than 0.05 was considered statistically significant.
177	
178	Results
170	Demographics and nationt characteristics
179	Demographics and patient characteristics
180	The serum samples were collected from 238 admitted hospital patients with
179 180 181	The serum samples were collected from 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection in General Hospital of Central Theater
179 180 181 182	The serum samples were collected from 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection in General Hospital of Central Theater Command of PLA from February 6 to February 14, 2020. The clinical characteristics
 179 180 181 182 183 	The serum samples were collected from 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection in General Hospital of Central Theater Command of PLA from February 6 to February 14, 2020. The clinical characteristics of the patients were shown in Table 1. The median age was 55 years (IQR, 38.3-65),
 179 180 181 182 183 184 	The serum samples were collected from 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection in General Hospital of Central Theater Command of PLA from February 6 to February 14, 2020. The clinical characteristics of the patients were shown in Table 1. The median age was 55 years (IQR, 38.3-65), and 138 (58.0%) of the patients were men. Hypertension (63 [26.5%]), diabetes (25
 179 180 181 182 183 184 185 	The serum samples were collected from 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection in General Hospital of Central Theater Command of PLA from February 6 to February 14, 2020. The clinical characteristics of the patients were shown in Table 1. The median age was 55 years (IQR, 38.3-65), and 138 (58.0%) of the patients were men. Hypertension (63 [26.5%]), diabetes (25 [10.5%]), and cardiovascular disease (24 [10.1%]) were the most common coexisting
 179 180 181 182 183 184 185 186 	The serum samples were collected from 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection in General Hospital of Central Theater Command of PLA from February 6 to February 14, 2020. The clinical characteristics of the patients were shown in Table 1. The median age was 55 years (IQR, 38.3-65), and 138 (58.0%) of the patients were men. Hypertension (63 [26.5%]), diabetes (25 [10.5%]), and cardiovascular disease (24 [10.1%]) were the most common coexisting disorders. Of these patients, the most common symptoms at illness onset were fever
 179 180 181 182 183 184 185 186 187 	The serum samples were collected from 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection in General Hospital of Central Theater Command of PLA from February 6 to February 14, 2020. The clinical characteristics of the patients were shown in Table 1. The median age was 55 years (IQR, 38.3-65), and 138 (58.0%) of the patients were men. Hypertension (63 [26.5%]), diabetes (25 [10.5%]), and cardiovascular disease (24 [10.1%]) were the most common coexisting disorders. Of these patients, the most common symptoms at illness onset were fever (206 [86.6%]), dry cough (128 [53.8%]), and fatigue (78 [32.8%]). A small number of
 179 180 181 182 183 184 185 186 187 188 	The serum samples were collected from 238 admitted hospital patients with confirmed or suspected SARS-CoV-2 infection in General Hospital of Central Theater Command of PLA from February 6 to February 14, 2020. The clinical characteristics of the patients were shown in Table 1. The median age was 55 years (IQR, 38.3-65), and 138 (58.0%) of the patients were men. Hypertension (63 [26.5%]), diabetes (25 [10.5%]), and cardiovascular disease (24 [10.1%]) were the most common coexisting disorders. Of these patients, the most common symptoms at illness onset were fever (206 [86.6%]), dry cough (128 [53.8%]), and fatigue (78 [32.8%]). A small number of patients possessed the symptoms of abdominal pain (1 [0.4%]), vomiting (3 [1.3%]),

190	41 (17.2%) patients and above the normal range in 21 (8.8%) patients. 125 (52.5%)
191	patients had lymphocytes below the normal range and no patients were found to have
192	lymphocytes above the normal range. Neutrophils were below the normal range in 28
193	(11.8%) patients and above the normal range in 32 (13.4%) patients. According to CT,
194	235 (98.7%) patients showed ground-glass opacity and/or patchy shadowing.
195	According to the positive or negative results of real time RT-PCR assay for
196	pharyngeal swab specimens, the enrolled patients were divided into two groups: the
197	confirmed group and the suspected group. There were no statistical differences of
198	baseline characteristics of the two groups patients.
199	Performance and validation of ELISA assays for viral specific IgM and IgG
200	antibodies
201	Each some sample of 229 patients were respectively tested for IaM and IaC
201	Each serum sample of 258 patients were respectively tested for igin and igo
201	antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N
201 202 203	antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N protein of SARS-CoV-2. The IgM and/or IgG could be detected in 194 serum samples,
201 202 203 204	antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N protein of SARS-CoV-2. The IgM and/or IgG could be detected in 194 serum samples, and the positive rate (81.5%) was significantly higher than that of SARS-CoV-2
 201 202 203 204 205 	antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N protein of SARS-CoV-2. The IgM and/or IgG could be detected in 194 serum samples, and the positive rate (81.5%) was significantly higher than that of SARS-CoV-2 RNA detected by real time RT-PCR, which was 64.3% (153/238) (Fig.1A).
 201 202 203 204 205 206 	antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N protein of SARS-CoV-2. The IgM and/or IgG could be detected in 194 serum samples, and the positive rate (81.5%) was significantly higher than that of SARS-CoV-2 RNA detected by real time RT-PCR, which was 64.3% (153/238) (Fig.1A). Importantly, there were no difference in positive rates of IgM and/or IgG between the
 201 202 203 204 205 206 207 	antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N protein of SARS-CoV-2. The IgM and/or IgG could be detected in 194 serum samples, and the positive rate (81.5%) was significantly higher than that of SARS-CoV-2 RNA detected by real time RT-PCR, which was 64.3% (153/238) (Fig.1A). Importantly, there were no difference in positive rates of IgM and/or IgG between the confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85)
202 203 204 205 206 207 208	antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N protein of SARS-CoV-2. The IgM and/or IgG could be detected in 194 serum samples, and the positive rate (81.5%) was significantly higher than that of SARS-CoV-2 RNA detected by real time RT-PCR, which was 64.3% (153/238) (Fig.1A). Importantly, there were no difference in positive rates of IgM and/or IgG between the confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85) (Fig.1B), suggesting that the clinically suspected patients, who were viral RNA
201 202 203 204 205 206 207 208 209	antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N protein of SARS-CoV-2. The IgM and/or IgG could be detected in 194 serum samples, and the positive rate (81.5%) was significantly higher than that of SARS-CoV-2 RNA detected by real time RT-PCR, which was 64.3% (153/238) (Fig.1A). Importantly, there were no difference in positive rates of IgM and/or IgG between the confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85) (Fig.1B), suggesting that the clinically suspected patients, who were viral RNA negative detected by RT-PCR, were mostly infected.
 201 202 203 204 205 206 207 208 209 210 	antibodies against SARS-CoV-2 by using newly-developed ELISA kits based on N protein of SARS-CoV-2. The IgM and/or IgG could be detected in 194 serum samples, and the positive rate (81.5%) was significantly higher than that of SARS-CoV-2 RNA detected by real time RT-PCR, which was 64.3% (153/238) (Fig.1A). Importantly, there were no difference in positive rates of IgM and/or IgG between the confirmed patients (83.0%, 127/153) and the suspected patients (78.8%, 67/85) (Fig.1B), suggesting that the clinically suspected patients, who were viral RNA negative detected by RT-PCR, were mostly infected. To verify the specificity of the ELISA assays, the serum samples from 70

212 detected. Four samples from the ordinary patients were identified as antibody positive

- 213 (including one dual positive sample, two IgM-positive samples, and one IgG-positive
- sample) and no positive was found in the samples of healthy blood donors (Fig.1A).
- 215 These results confirmed the specificity of the IgG and IgM ELISA assays.

216 Dynamic analysis of ELISA and RT-PCR assays

217 To study the diagnostic value of ELISA assay for virus-specific antibodies,

especially in the early stage of the disease, we tried to analyze the positive rates of

219 ELISA and RT-PCR assays in the different stages of disease. To this end, each patient

220 was assigned to different days after initial onset of symptoms based on the time when

the pharyngeal swab specimen was detected to be positive or the last recoded

222 detection was still negative, or the blood was collected. The positive rates of viral

- 223 RNA, IgM and/or IgG were compared in every day after initial onset of symptoms
- (Table 2). Due to a small number of samples in each individual day, we pooled the

samples in which the positive rates were similar in consecutive days. Thus, the disease

process were divided into five phases of 0-5, 6-10,11-12, 13-15 days and more than

227 16 days after initial onset of symptoms (Table 3 & Fig.2). The data showed that

228 positive rates of IgM and/or IgG were very low in the first five days after initial onset

of symptoms because there was no antibody produced in most of patients in this early

stage, and then rapidly increased as the disease progressed. Day 11 after initial onset

of symptoms is a key time point because the positive rates of IgM and/or IgG jumped

to above 80% from less than 50% at this time point. The dynamic pattern is consistent

233 with SARS-CoV infection. ²¹ On the contrary, the real-time RT-PCR was more

234	effective for detecting SARS-CoV-2 infection than ELISA in the early stage of disease.
235	The positive rate of viral RNA detected by RT-PCR was maintained above 60% in the
236	first 11 days after initial onset of symptoms, and then rapidly decreased with the rapid
237	increase of positive rate of antibodies. These results demonstrated that ELISA-based
238	IgM and/or IgG detection should be used as a major viral diagnostic test for the
239	patients with symptoms for more than 10 days. Because about 50%
240	clinically-suspected patients with symptoms for 6-10 days were detected to be
241	positive by ELISA-based IgM and/or IgG detection (Table 4), the combination of
242	ELISA and RT-PCR assays will greatly improve the detection efficacy, even in the
243	early stage of COVID-19 infection.
244	
245	Discussion
246	The outbreak of the recently emerged novel coronavirus (SARS-CoV-2) poses a
247	challenge for public health laboratories, especially for clinical laboratories of the
248	hospitals in Wuhan, China. Although serological assay is a frequently used method for
249	viral infection screening and diagnosis, there are few reports about serological assay
250	in detection of SARS-CoV-2 up to now. In this study, we report the application of the
251	SARS-CoV-2 N protein-based ELISA for detection of IgM and IgG antibodies in the
252	admitted hospital patients with confirmed or suspected SARS-CoV-2 infection. The

- results showed that the positive rates of IgM and IgG were significantly higher than
- that of viral RNA detected by real-time RT-PCR on the pharyngeal swab specimens of
- all enrolled patients. This result is further supported by the fact that the suspected

patients had the same positive rate of antibody as the confirmed patients. These data
strongly demonstrated that the clinically suspected patients were mostly infected by
SARS-CoV-2.

259	In this study, the serum samples were collected in a time period of 9 days from
260	the patients in different stages of disease. The positive rates of nucleic acid test and
261	serological assay in total populations cannot reflect their diagnostic value in
262	surveillance and control of the disease, because the production of antiviral antibodies
263	will decrease the positive rates of the nucleic acid test as the disease progresses. In
264	order to objectively determine the disease stage of the patients, we used the initial
265	onset of symptoms of the patients as the start time point. Based on the day when the
266	test sample was collected, all patients were defined to the different stages of disease.
267	The resulted dynamics patterns of positive rates of viral RNA and antiviral antibodies
268	proved the rationality of the disease stage definition. Our analysis identified the 11th
269	day after initial onset of symptoms as a key time point in the disease process when
270	most infected patients produce antiviral antibodies. After this time point, the diagnosis
271	for viral infection should majorly depend on serological assay. Before this time point,
272	nucleic acid test is important for confirmation of viral infection. The combination of
273	serological assay can greatly improve the diagnostic efficacy.
274	According to the rapid advice guideline for the diagnosis and treatment of
275	SARS-CoV-2 currently implemented in China, ²⁰ a confirmed case of COVID-19
276	patients exclusively depends on the positive result of nucleic acid test or virus gene
277	sequencing. Although this is a preliminary ELISA assay for SARS-CoV-2, our study

278	strongly	demonstrate	that sero	logical	assay is	very	important	for s	surveillance	and
-----	----------	-------------	-----------	---------	----------	------	-----------	-------	--------------	-----

- 279 control of the current COVID-19, especially in Wuhan of China, where a lot of
- 280 patients are waiting to be confirmed at present. Moreover, most of patients had
- symptoms for more than 11 days.
- 282 Acknowledgements
- 283 This work was supported by the National Natural Science Foundation of China
- 284 (81801984, 81830003); the National Key Research and Development Program of
- 285 China (2019YFC130030); and the China Postdoctoral Science Foundation
- 286 (2019M664008). We thank all heathy-care workers involved in this study. We thank
- 287 Wuhan Institute of Virology of Chinese Academy of Sciences and Zhuhai Lizhu
- 288 Diagnostics Inc. for providing assistance in ELISA detection.

289 **Conflict of interest**

290 The authors declare that no conflict of interest exists.

291 Authors' contributions

- 292 S.Z., S.W., and L.L. conceived the study and designed experimental procedures;
- 293 W.L., Y.Z., W.N., Y.D., W.W., S.T., X.J., J.D., Q.H., Z.H., W.X., Y.Z., B.Z., Z.T.,
- 294 X.Z., H.L., Z.R., H.J., and X.R. collected patients' samples. Q.W. and L.T. performed
- viral RNA tests. G.K., W.L. W.N., and Y.Z established ELISA and performed
- serological assays. S.W., L.L., S.Z., and W.L. wrote the paper. All authors contributed
- to data acquisition, data analysis, or data interpretation, and reviewed and approved
- the final version.

300 References

- 301 1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:
- 302 implications for virus origins and receptor binding. *Lancet* 2020; published online Jan 30. Doi:
- 303 10.1016/S0140-6736(20)30251-8.
- 2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus
- 305 in Wuhan, China. *Lancet* 2020; 395(10223):497-506.
- 306 3. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
- 307 Coronavirus-Infected Pneumonia. N Engl J Med 2020; published online Jan 29. Doi:
- 308 10.1056/NEJMoa2001316.
- 309 4. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international
- 310 spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020;
- 311 published online Jan 31. Doi: 10.1016/S0140-6736(20)30260-9.
- 312 5. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel
- coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020;
 395(10223):514-523.
- Beiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. *Nat Med* 2004;10(12
 Suppl):S88-97.
- 317 7. Lee J, Chowell G, Jung E. A dynamic compartmental model for the Middle East respiratory
- syndrome outbreak in the Republic of Korea: A retrospective analysis on control interventions and
 superspreading events. *J Theor Biol* 2016;408:118-26.
- 320 8. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China,
 321 2019. *N Engl J Med* 2020; 382(8):727-733.
- 322 9. Delmas B, Laude H. Assembly of coronavirus spike protein into trimers and its role in epitope
 323 expression. *J Virol* 1990;64(11):5367-75.
- Neuman BW, Kiss G, Kunding AH, et al. A structural analysis of M protein in coronavirus
 assembly and morphology. *J Struct Biol* 2011;174(1):11-22.
- 326 11. Nieto-Torres JL, DeDiego ML, Verdia-Baguena C, et al. Severe acute respiratory syndrome
- coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. *PLoS Pathog* 2014;10(5):e1004077.
- Chang CK, Sue SC, Yu TH, et al. Modular organization of SARS coronavirus nucleocapsid
 protein. *J Biomed Sci* 2006;13(1):59-72.
- Hurst KR, Koetzner CA, Masters PS. Identification of in vivo-interacting domains of the murine
 coronavirus nucleocapsid protein. *J Virol* 2009;83(14):7221-34.
- 14. Cui L, Wang H, Ji Y, et al. The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor
 of RNA Silencing in Mammalian Cells. *J Virol* 2015;89(17):9029-43.
- 335 15. Narayanan K, Chen CJ, Maeda J, et al. Nucleocapsid-independent specific viral RNA packaging
- via viral envelope protein and viral RNA signal. J Virol 2003;77(5):2922-7.
- 337 16. Che XY, Qiu LW, Pan YX, et al. Sensitive and specific monoclonal antibody-based capture
- enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute
- 339 respiratory syndrome. J Clin Microbiol 2004;42(6):2629-35.
- 340 17. Guan M, Chen HY, Foo SY, et al. Recombinant protein-based enzyme-linked immunosorbent
- 341 assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute
- 342 respiratory syndrome (SARS) coronavirus in SARS patients. Clin Diagn Lab Immunol

- 343 2004;11(2):287-91.
- 344 18. Woo PC, Lau SK, Wong BH, et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and
- 345 IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein
- in patients with pneumonia due to the SARS coronavirus. *Clin Diagn Lab Immunol* 2004;11(4):665-8.
- 347 19. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis.
- 348 J Med Virol 2020; 92(4):418-423.
- 349 20. General Office of National Health Committee. Office of State Administration of Traditional
- 350 Chinese Medicine. Notice on the issuance of strategic guidelines for diagnosis and treatment of novel
- 351 coronavirus (2019-nCoV) infected pneumonia (Fifth edition draft) (2020-02-09) [EB/OL].
- 352 http://bgs.satcm.gov.cn/zhengcewenjian/2020-02-09/12930.html.
- 353 21. Chen S, Lu D, Zhang M, et al. Double-antigen sandwich ELISA for detection of antibodies to
- 354 SARS-associated coronavirus in human serum. Eur J Clin Microbiol Infect Dis 2005;24(8):549-53.

Characteristics	All patients (N=238)	Confirmed (N=153)	Suspected (N=85)	P v	
Age, Median (IQR) – y	55.0 (38.3-65.0)	54.0 (39.0-64.0)	55.0 (38.0-65.0)	0.6	
Sex					
Male	138 (58.0%)	93 (60.8%)	45 (52.3%)		
Female	100 (42.0%)	60 (39.2%)	40 (47.6%)	0.2	
Vital signs					
Heart rate	89 (80-100)	89 (80-99)	90 (80-104)	0.4	
Respiratory rate	18 (18-20)	19 (18-20)	18 (18-20)	0.	
Oxygen saturation	96% (94%-98%)	96% (94%-98%)	97% (95%-98%)	0.	
CT findings of ground-glass					
opacity and/or patchy	235/238 (98.7)	151/153 (98.7)	84/85 (98.8)	0.	
shadowing					
Leukocytes (×10 ⁹ per L; normal					
range 3.5-9.5)					
Decreased	41/238 (17.2)	25/153 (16.3)	16/85 (18.8)	0.	
Increased	21/238 (8.8)	16/153 (10.5)	5/85 (5.9)	0.	
Lymphocytes (×10 ⁹ per L;					
normal range 1.1-3.2)					
Decreased	125/238 (52.5)	84/153 (54.9)	41/85 (48.2)	0.	
Neutrophils (×10 ⁹ per L; normal					
range 1.8-6.3)					
Decreased	28/238 (11.8)	17/153 (11.1)	11/85 (12.9)	0.	
Increased	32/238 (13.4)	22/153 (14.4)	10/85 (11.8)	0.	
Signs and symptoms					
Fever	206/238 (86.6)	134/153 (87.6)	72/85 (84.7)	0.	
Dry cough	128/238 (53.8)	86/153 (56.2)	42/85 (49.4)	0.	
Fatigue	78/238 (32.8)	47/153 (30.7)	31/85 (36.5)	0.	
Myalgia	46/238 (19.3)	29/153 (19.0)	17/85 (20.0)	0.	
Dyspnea	44/238 (18.5)	31/153 (20.3)	13/85 (15.3)	0.	
Chill	31/238 (13.0)	20/153 (13.1)	11/85 (12.9)	0.	
Anorexia	29/238 (12.2)	14/153 (9.2)	15/85 (17.6)	0.	
Diarrhea	24/238 (10.1)	14/153 (9.2)	10/85 (11.8)	0.	
Expectoration	21/238 (8.8)	14/153 (9.2)	7/85 (8.2)	0.	
Headache	15/238 (6.3)	12/153 (7.8)	3/85 (3.5)	0.	
Pharyngalgia	14/238 (5.9)	9/153 (5.9)	6/85 (7.1)	0.	
Palpitation	9/238 (3.8)	8/153 (5.2)	1/85 (1.2)	0.	
Chest pain	6/238 (2.5)	4/153 (2.6)	2/85 (2.4)	0.	
Nausea	4/238 (1.7)	2/153 (1.3)	2/85 (2.4)	0.	
Dizziness	4/238 (1.7)	4/153 (2.6)	0/85 (0.0)	0.	
Vomiting	3/238 (1.3)	3/153 (2.0)	0/85 (0.0)	0.	
Abdominal pain	1/238 (0.4)	1/153 (0.7)	0/85 (0.0)	0.	
Coexisting disorders					
Hypertension	63/238 (26.5)	42/153 (27.5)	21/85 (24.7)	0.	

Diabetes	25/238 (10.5)	15/153 (9.8)	10/85 (11.8)	0.636
Cardiovascular disease	24/238 (10.1)	16/153 (10.5)	8/85 (9.4)	0.797
Malignancy	12/238 (5.0)	6/153 (3.9)	6/85 (7.1)	0.289
Cerebrovascular disease	8/238 (3.4)	5/153 (3.3)	3/85 (3.5)	0.915
COPD	3/238 (1.3)	1/153 (0.7)	2/85 (2.4)	0.260

357 Data are median (IQR), n (%), or n/N (%), where N is the total number of patients with available data. P values comparing the

358 confirmed patients and the suspected patients are from χ^2 test, Fisher's exact test, or Mann-Whitney U test. Confirmed=confirmed

359 patients. Suspected=suspected patients.

360

361

362

363	Table 2. Viral RNA and antibody positive rates of the patients detected each day
364	from initial onset of symptoms

Day	Viral RNA ⁺	IgM ⁺ and/or IgG ⁺	IgM^+	IgG^+	IgM ⁺ and IgG ⁺
0	100.0 (2/2)	50.0 (1/2)	0.0 (0/2)	50.0 (1/2)	0.0 (0/2)
1	83.3 (5/6)	33.3 (1/3)	0.0 (0/3)	33.3 (1/3)	0.0 (0/3)
2	71.4 (5/7)	0.0 (0/3)	0.0 (0/3)	0.0 (0/3)	0.0 (0/3)
3	61.5 (8/13)	25.0 (1/4)	25.0 (1/4)	0.0 (0/4)	0.0 (0/4)
4	69.2 (9/13)	50.0 (2/4)	0.0 (0/4)	0.0 (0/4)	50.0 (2/4)
5	92.3 (12/13)	0.0 (0/1)	0.0 (0/1)	0.0 (0/1)	0.0 (0/1)
6	62.5 (5/8)	60.0 (3/5)	0.0 (0/5)	0.0 (0/5)	60.0 (3/5)
7	88.9 (8/9)	50.0 (2/4)	25.0 (1/4)	0.0 (0/4)	25.0 (1/4)
8	81.8 (18/22)	54.5 (6/11)	18.2 (2/11)	0.0 (0/11)	36.4 (4/11)
9	85.0 (17/20)	42.9 (6/14)	7.1 (1/14)	7.1 (1/14)	28.6 (4/14)
10	75.0 (9/12)	42.9 (3/7)	14.3 (1/7)	0.0 (0/7)	28.6 (2/7)
11	72.2 (13/18)	81.8 (9/11)	18.2 (2/11)	27.3 (3/11)	36.4 (4/11)
12	50.0 (5/10)	80.0 (8/10)	30.0 (3/10)	20.0 (2/10)	30.0 (3/10)
13	44.4 (4/9)	90.9 (10/11)	27.3 (3/11)	9.1 (1/11)	54.5 (6/11)
14	69.2 (9/13)	100.0 (17/17)	29.4 (5/17)	0.0 (0/17)	70.6 (12/17)
15	30.8 (4/13)	90.0 (18/20)	10.0 (2/20)	15.0 (3/20)	65.0 (13/20)
16	50.0 (4/8)	100.0 (16/16)	12.5 (2/16)	25.0 (4/16)	62.5 (10/16)
17	57.1 (4/7)	88.9 (16/18)	0.0 (0/18)	5.6 (1/18)	83.3 (15/18)
18	33.3 (2/6)	100.0 (16/16)	0.0 (0/16)	6.3 (1/16)	93.8 (15/16)
19	33.3 (3/9)	100.0 (19/19)	10.5 (2/19)	21.1 (4/19)	68.4 (13/19)
20	0.0 (0/1)	83.3 (5/6)	0.0 (0/6)	33.3 (2/6)	50.0 (3/6)
>20	36.8 (7/19)	97.2 (35/36)	2.8 (1/36)	8.3 (3/36)	86.1 (31/36)

365 Data are % (n/N). Day= the day after initial onset of symptoms. Viral RNA⁺=a positive result detected by real time RT-PCR.

366 IgM⁺=a positive result detected by IgM ELISA and simultaneously a negative result detected by IgG ELISA. IgG⁺=a positive

367 result detected by IgG ELISA and simultaneously a negative result detected by IgM ELISA. IgM⁺ and IgG⁺=a dual positive result

368 detected by IgM and IgG ELISA. IgM⁺and/or IgG⁺=at least a positive result detected by IgM and IgG ELISA.

369

370

Table 3. Viral RNA and antibody positive rates of the patients detected in different stages of disease

Days	Viral RNA ⁺	IgM ⁺ and/or IgG ⁺	IgM ⁺	IgG ⁺	IgM ⁺ and IgG ⁺	
0-5	75.9 (41/54)	29.4 (5/17)	5.9 (1/17)	11.8 (2/17)	11.8 (2/17)	
6-10	80.3 (57/71)	48.8 (20/41)	12.2 (5/41)	2.4 (1/41)	34.1 (14/41)	
11-12	64.3 (18/28)	81.0 (17/21)	23.8 (5/21)	23.8 (5/21)	33.3 (7/21)	
13-15	48.6 (17/35)	93.8 (45/48)	20.8 (10/48)	8.3 (4/48)	64.6 (31/48)	
≥16	40.0 (20/50)	96.4 (107/111)	4.5 (5/111)	13.5 (15/111)	78.4 (87/111)	
Total	64.3 (153/238)	81.5 (194/238)	10.9 (26/238)	11.3 (27/238)	59.2 (141/238)	

377 Data are % (n/N). Days= the day after initial onset of symptoms. Viral RNA⁺=a positive result detected by real time RT-PCR.

378 IgM⁺=a positive result detected by IgM ELISA and simultaneously a negative result detected by IgG ELISA. IgG⁺=a positive

result detected by IgG ELISA and simultaneously a negative result detected by IgM ELISA. IgM⁺ and IgG⁺=a dual positive result

 $380 \qquad \text{detected by IgM and IgG ELISA. IgM^+and/or IgG^+=at least a positive result detected by IgM and IgG ELISA.}$

Table 4. Comparison of the antibody positive rates between the confirmed and suspected patients

 ···· ·································				
	0-5 days	6-10 days	≥11 days	
Confirmed	55.6 (5/9)	44.0 (11/25)	93.3 (111/119)	
Suspected	0.0 (0/8)	56.3 (9/16)	95.1 (58/61)	

388 Data are % (n/N). Confirmed=confirmed patients. Suspected=suspected patients.



Figure 1. Positive rate of viral RNA and antibody in different samples. A) The positive rate of viral RNA (black column) and antibody (white column) in 238 enrolled patients (two columns on the left), as well as the positive rate of antibody in ordinary patients and healthy donors (two columns on the right). B) Comparison of positive rate of antibody between the laboratory-confirmed (left) and highly-suspected patients (right). Results were compared by chi-square tests.



410

411 Figure 2. Dynamics of the positive rate of viral RNA and antibody of the patients

412 at the different stages of disease. The disease courses were divided into five phases

413 of 0-5, 6-10,11-12, 13-15 days and more than 16 days after initial onset of symptoms.

414 The positive rate of viral RNA (solid circle) and antibody (hollow circle) of the

- 415 patients at the different phase of disease was shown.
- 416